Lytgobi (futibatinib) — Medica

Initial criteria

• age ≥ 18 years
• Patient has unresectable locally advanced or metastatic disease
• Tumor has fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements as detected by an approved test
• Patient has been previously treated with at least one systemic regimen

Approval duration

1 year